Rebecca Byam Buys 5,000 Shares of HCW Biologics Inc. (NASDAQ:HCWB) Stock

HCW Biologics Inc. (NASDAQ:HCWB) CFO Rebecca Byam acquired 5,000 shares of the business’s stock in a transaction dated Friday, September 8th. The stock was bought at an average cost of $2.02 per share, with a total value of $10,100.00. Following the acquisition, the chief financial officer now owns 558,946 shares in the company, valued at approximately $1,129,070.92. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Rebecca Byam also recently made the following trade(s):

• On Wednesday, September 6th, Rebecca Byam bought 5,000 shares of HCW Biologics stock. The stock was purchased at an average cost of $1.95 per share, for a total transaction of $9,750.00.

HCW Biologics Stock Up 5.1 %

Shares of HCWB stock opened at $2.05 on Friday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.36 and a current ratio of 4.36. The firm’s 50-day moving average is $2.06 and its 200-day moving average is $1.79. The stock has a market cap of $73.66 million, a price-to-earnings ratio of -3.73 and a beta of 1.24. HCW Biologics Inc. has a 52-week low of $1.08 and a 52-week high of $2.79.

HCW Biologics (NASDAQ:HCWB) last issued its earnings results on Friday, August 11th. The company reported ($0.12) earnings per share (EPS) for the quarter. The firm had revenue of $0.62 million for the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in HCWB. HighTower Advisors LLC increased its holdings in shares of HCW Biologics by 2,056.0% during the 1st quarter. HighTower Advisors LLC now owns 215,598 shares of the company’s stock worth $588,000 after acquiring an additional 205,598 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of HCW Biologics by 136.8% during the 1st quarter. BlackRock Inc. now owns 39,583 shares of the company’s stock worth $108,000 after buying an additional 22,869 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of HCW Biologics by 9.8% during the 3rd quarter. Vanguard Group Inc. now owns 95,392 shares of the company’s stock worth $218,000 after buying an additional 8,494 shares during the period. 2.79% of the stock is owned by institutional investors and hedge funds.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.